Envestnet Asset Management Inc. Sells 1,258 Shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Envestnet Asset Management Inc. decreased its position in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 6.4% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 18,436 shares of the company’s stock after selling 1,258 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.51% of Invesco Biotechnology & Genome ETF worth $1,170,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of PBE. JPMorgan Chase & Co. lifted its stake in shares of Invesco Biotechnology & Genome ETF by 30.0% during the fourth quarter. JPMorgan Chase & Co. now owns 650 shares of the company’s stock valued at $43,000 after acquiring an additional 150 shares during the period. Capital Analysts LLC raised its holdings in Invesco Biotechnology & Genome ETF by 55.9% during the 4th quarter. Capital Analysts LLC now owns 1,715 shares of the company’s stock worth $114,000 after purchasing an additional 615 shares during the last quarter. Beese Fulmer Investment Management Inc. acquired a new position in Invesco Biotechnology & Genome ETF during the 1st quarter valued at about $216,000. Wealth Enhancement Advisory Services LLC lifted its position in Invesco Biotechnology & Genome ETF by 10.6% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,066 shares of the company’s stock valued at $271,000 after purchasing an additional 390 shares during the period. Finally, Janney Montgomery Scott LLC boosted its stake in shares of Invesco Biotechnology & Genome ETF by 12.5% in the 1st quarter. Janney Montgomery Scott LLC now owns 5,424 shares of the company’s stock valued at $344,000 after purchasing an additional 604 shares during the last quarter.

Invesco Biotechnology & Genome ETF Price Performance

Shares of NYSEARCA:PBE opened at $65.54 on Friday. The company has a 50 day moving average of $64.81 and a 200-day moving average of $64.46. Invesco Biotechnology & Genome ETF has a one year low of $54.52 and a one year high of $72.84. The stock has a market cap of $226.11 million, a price-to-earnings ratio of 20.44 and a beta of 0.87.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.